Bio4t2 announces trial evaluating repeat infusions of CAR-T targeting solid tumors without lymphodepletion

/PRNewswire/ -- Bio4t2® received regulatory approvals to repeatedly administer patients with T cells engineered to express a chimeric antigen receptor (CAR)...

Related Keywords

Shanghai ,China ,United States ,Farzad Haerizadeh ,Jenny Bourbiel ,Prnewswire Bio ,Bridgewest Group ,Laurence Cooper ,Executive Chairman ,Chief Scientific Officer ,Shanghai East ,Shanghai Artemed ,Bio4t2 ,